Cancer cell subpopulations responsible for early relapses, new study shows
This article was originally published in Scrip
Tumour cell heterogeneity may mean that individual cancers are already inherently resistant to current drug therapies before treatment begins, according to a small study in cervical cancer from researchers at Cancer Research UK institutes in Cambridge and Edinburgh. Lead study author, Dr Susanna Cooke, explained that genotyping of biopsies taken from cervical tumours shows that more than one type of cell may be present when the treating physician first sees the disease. Subsequent treatment can drastically reduce the quantity of susceptible cells, but the residual population of cells then grows through, causing rapid, therapy-resistant remission.
You may also be interested in...
Charting the executive gender mix across 384 companies from mid-2014 to mid-2019 demonstrates that C-suite gender balance in pharma is moving towards a point that more closely reflects its total workforce, but that progress has been slow and that there is a long road to travel before the transformation is complete.
With gender diversity only slowly increasing in biopharma c-suites, Scrip spoke to executives from five companies about the importance of change.
In a flat month, the market value of big pharma changed little overall. But the balance of power in immuno-oncology did shift significantly.